Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PMTC, CRWE, RRD, PWRM, LOPE - Board of Directors Stock News Alert for Wednesday October 27th, 2010





Parametric Technology Corporation (Nasdaq:PMTC) posted fourth-quarter net earnings in line with expectations and said that sales would be sequentially lower in the December quarter. The Needham, Massachusetts-based company said its first-quarter sales would dip to between $255 million and $265 million, which is in line with what analysts had expected.

Parametric Technology's revenue was $268 million in the fourth quarter, a bit above analysts' average expectations of $264 million, according to Thomson Reuters.

Parametric Technology Corporation develops, markets, and supports product lifecycle management (NYSEMKT:PLM) software solutions and related services enabling companies that enhance their product development processes.


Crown Equity Holdings Inc. (the “Company”) (OTC:CRWE)

Last Trade: $0.05 (+$0.008 or +19.05% UP) with over 229,600 shares traded so far

The Second Time Around - When you gotta grow, you gotta grow.

First, Crown Equity Holdings Inc. (OTCPK:CRWE) announced in June of this year its 1- 10 forward stock split, as well as in

August announcing that the company had surpassed One Million dollars (1,000,000) in sales. Now it is touting its expansion

by opening a second office in Pakistan, which will add an additional workforce of 25 associates to its CRWE Newswire team

and increase coverage of up-to-date news and world affairs from the Mideast, Far East, and Europe via its online


Another Office in Pakistan

The company is utilizing today’s technology to advertise, promote and market public companies globally. CRWE’s proprietary

network technology allows its publishing department to get its content to millions of readers daily across the world. CRWE

publishes financial content to all the major countries and covers all the accredited stock exchanges. The goal for 2010 is

to have all CRWE’s clients’ press releases, articles and news content published in every major financial country’s native


Check out the activity of the Year to Date chart for CRWE!

Crown Equity Holdings Website



R.R. Donnelley & Sons Company (Nasdaq:RRD) announced on October 21, 2010 that pursuant to the terms of the Merger Agreement entered into among RR Donnelley, Bowne and Snoopy Acquisition, Inc. on February 23, 2010, the termination date of the Merger Agreement has been extended as provided for in the Merger Agreement from October 23, 2010 to January 23, 2011.

RR Donnelley and Bowne had previously disclosed on May 12, 2010, that each had received a request for additional information (commonly known as a "second request") from the Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Completion of the transaction remains subject to the expiration or termination of the waiting period under the HSR Act and other customary closing conditions. RR Donnelley and Bowne continue to expect the transaction to close during 2010.

RR Donnelley (Nasdaq:RRD) is a global provider of integrated communications. Founded more than 146 years ago, the company works collaboratively with more than 60,000 customers worldwide to develop custom communications solutions that reduce costs, enhance ROI and ensure compliance.





PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

Power3 Medical Products, Inc., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

"In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

"We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of Power3, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."

"We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.


Grand Canyon Education, Inc. (Nasdaq:LOPE) announced that it will report its 2010 third quarter results after market close on Tuesday, November 9, 2010. The Company will host a conference call to discuss the results in more detail at 3:00 p.m. (5:00 p.m. ET) the same day.

Grand Canyon Education, Inc. is a regionally accredited provider of postsecondary education services focused on offering graduate and undergraduate degree programs in its core disciplines of education, business, healthcare, and liberal arts. It offers programs online as well as ground programs at its 100 acre traditional campus in Phoenix, Arizona and onsite at the facilities of employers.



Sign-Up For Free Stock Alerts At

business card


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).